Grainne  Quinn net worth and biography

Grainne Quinn Biography and Net Worth

EVP of Perrigo
Grainne Quinn was named Executive Vice President in July 2016 and has served as Chief Medical Officer since November 2015. Prior to that she served as Vice President and Head of Global Patient Safety from January 2014 until November 2015. Dr. Quinn was Vice President and Head of Global Pharmacovigilance and Risk Management in Elan from April 2009 until December 2013 when the Company acquired Elan. Previously she had held various medical roles in Quintiles. Dr. Quinn was Board Certified in Internal Medicine in 1995 and practiced in the United States for several years prior to joining the pharmaceutical industry.

What is Grainne Quinn's net worth?

The estimated net worth of Grainne Quinn is at least $247,553.70 as of December 16th, 2022. Ms. Quinn owns 9,118 shares of Perrigo stock worth more than $247,554 as of November 21st. This net worth approximation does not reflect any other investments that Ms. Quinn may own. Learn More about Grainne Quinn's net worth.

How do I contact Grainne Quinn?

The corporate mailing address for Ms. Quinn and other Perrigo executives is THE SHARP BUILDING HOGAN PLACE, DUBLIN L2, 49010. Perrigo can also be reached via phone at (531) 709-4000 and via email at [email protected]. Learn More on Grainne Quinn's contact information.

Has Grainne Quinn been buying or selling shares of Perrigo?

Grainne Quinn has not been actively trading shares of Perrigo during the last ninety days. Most recently, Grainne Quinn sold 2,368 shares of the business's stock in a transaction on Friday, December 16th. The shares were sold at an average price of $31.65, for a transaction totalling $74,947.20. Following the completion of the sale, the executive vice president now directly owns 9,118 shares of the company's stock, valued at $288,584.70. Learn More on Grainne Quinn's trading history.

Who are Perrigo's active insiders?

Perrigo's insider roster includes Bradley Alford (Director), Svend Andersen (EVP), Eduardo Bezerra (CFO), Rolf Classon (Director), James Dillard, III (EVP), Thomas Farrington (EVP), Alison Ives (EVP), Ronald Janish (EVP), Murray Kessler (CEO), Todd Kingma (VP), Patrick Lockwood-Taylor (CEO), Geoffrey Parker (Director), Grainne Quinn (EVP), Theodore Samuels, II (Director), Raymond Silcock (CFO), Richard Sorota (EVP), and Robert Willis (EVP). Learn More on Perrigo's active insiders.

Are insiders buying or selling shares of Perrigo?

During the last twelve months, Perrigo insiders bought shares 5 times. They purchased a total of 24,540 shares worth more than $675,232.90. During the last twelve months, insiders at the sold shares 3 times. They sold a total of 50,254 shares worth more than $1,411,969.20. The most recent insider tranaction occured on September, 13th when Director Katherine C Doyle sold 8,954 shares worth more than $244,444.20. Insiders at Perrigo own 0.7% of the company. Learn More about insider trades at Perrigo.

Information on this page was last updated on 9/13/2024.

Grainne Quinn Insider Trading History at Perrigo

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/16/2022Sell2,368$31.65$74,947.209,118View SEC Filing Icon  
11/11/2019Sell2,050$49.08$100,614.003,047View SEC Filing Icon  
See Full Table

Grainne Quinn Buying and Selling Activity at Perrigo

This chart shows Grainne Quinn's buying and selling at Perrigo by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Perrigo Company Overview

Perrigo logo
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $27.15
Low: $26.80
High: $27.30

50 Day Range

MA: $25.98
Low: $24.18
High: $28.21

2 Week Range

Now: $27.15
Low: $23.89
High: $34.60

Volume

1,232,012 shs

Average Volume

1,783,506 shs

Market Capitalization

$3.70 billion

P/E Ratio

N/A

Dividend Yield

4.05%

Beta

0.48